Antidepressant drug development: Focus on triple monoamine reuptake inhibition

Journal of Psychopharmacology

Volumn 29, Issue 5, 2015, Pages 526-544

  Lane, Roger M ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Abuse liability; decreased positive mood symptoms; dopamine; endophenotype; neurocircuit; predictive enrichment; reward network; target engagement; translational medicine; treatment resistant depression; triple monoamine reuptake inhibition

Indexed keywords

1 [1 (4 CHLOROPHENYL)CYCLOBUTYL] 3 METHYLBUTANAMINE; 3 (3,4 DICHLOROPHENYL) 2 (METHOXYMETHYL) 8 AZABICYCLO[3.2.1]OCTANE; AMINEPTINE; AMITIFADINE; ANTIDEPRESSANT AGENT; ARMODAFINIL; CATECHOL METHYLTRANSFERASE; DULOXETINE; ESCITALOPRAM; IMIPRAMINE; LIAFENSINE; LISDEXAMFETAMINE; METHYLPHENIDATE; MODAFINIL; NOMIFENSINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRIPLE REUPTAKE INHIBITOR; VENLAFAXINE; ADRENERGIC RECEPTOR AFFECTING AGENT; DOPAMINE UPTAKE INHIBITOR; DRUG COMBINATION;

AGITATION; ALERTNESS; AMYGDALOID NUCLEUS; ANHEDONIA; ANOREXIA; ANTIDEPRESSANT ACTIVITY; ANXIETY; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUTOIMMUNE HEMOLYTIC ANEMIA; CARDIOVASCULAR DISEASE; COGNITION; COMORBIDITY; DECISION MAKING; DEPRESSION; DISGUST; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG RESPONSE; DSM-5; ENDOPHENOTYPE; FEAR; FUNCTIONAL NEUROIMAGING; GASTROINTESTINAL DISEASE; GENE FUNCTION; GENE SILENCING; GLUTAMATERGIC SYNAPSE; GUILT; HAPPINESS; HEART PALPITATION; HOSTILITY; HUMAN; HYPERPHAGIA; HYPERSOMNIA; ICD-10; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; LIVER TOXICITY; LONELINESS; MAJOR DEPRESSION; MESOLIMBIC DOPAMINERGIC SYSTEM; MONOAMINERGIC SYSTEM; MOOD; MOTIVATION; NAUSEA; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NUCLEUS ACCUMBENS; PATHOPHYSIOLOGY; PESSIMISM; PLEASURE; PREFRONTAL CORTEX; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; REMISSION; RESTLESSNESS; REWARD; SIDE EFFECT; SLEEP DISORDER; TACHYCARDIA; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; VENTRAL HIPPOCAMPUS; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; DEPRESSIVE DISORDER, MAJOR; DRUG COMBINATION; DRUG DESIGN;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOPAMINE UPTAKE INHIBITORS; DRUG COMBINATIONS; DRUG DESIGN; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 84930643605     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114553252     Document Type: Article

References (267)

1. Aarts E, van Holstein M, Cools R. Striatal dopamine and the interface between motivation and cognition. Front Psychol. 2011 ; 2: 163
2. Abbasowa L, Kessing LV, Vinberg M. Psychostimulants in moderate to severe affective disorder: A systematic review of randomized controlled trials. Nord J Psychiatry. 2013 ; 67: 369-382
3. Ainsworth C. Networking for new drugs. Nat Med. 2011 ; 17: 1166-1168
4. Airan RD, Meltzer LA, Roy M, et al. High-speed imaging reveals neurophysiological links to behavior in an animal model of depression. Science. 2007 ; 317: 819-823
5. Albany Molecular Research Inc. (2013) Item 8.01: Other events. Form 8-K. Current report filing to Securities and Exchange Commission, USA, 9August.
6. Alevizos B, Christodoulou GN, Loannidis C, et al. The efficacy of amineptine in the treatment of depressive patients with irritable bowel syndrome. Clin Neuropharmacol. 1989 ; 12: S66-76
7. Alloy LB, Ambramson LY, Raniere D, et al Handbook of Research Methods in Clinical Psychology. 1999 ) Research methods in adult psychopathology. In: KendallPCButcherJNHolmbeckGN (eds.) Handbook of Research Methods in Clinical Psychology (2nd ed). New York: Wiley, pp. 466-498. Kendall PC Butcher JN Holmbeck GN, ed. New York: Wiley ; 1999: 466-498.
8. Diagnostic and statistical manual of mental disorders. 2013 ) Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: American Psychiatric Publishing. Washington, DC: American Psychiatric Publishing ; 2013 :
9. Argyelán M, Szabó Z, Kanyó B, et al. Dopamine transporter availability in medication free and in bupropion treated depression: A 99mTc-TRODAT-1 SPECT study. J Affect Disord. 2005 ; 89: 115-123
10. Baldomero EB, Ubago JG, Cercos CL, et al. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety. 2005 ; 22: 68-76
11. Baldwin DS, Papakostas GI. Symptoms of fatigue and sleepiness in major depressive disorder. J Clin Psychiatry. 2006 ; 67: 9-15
12. Bergman J, Madras BK, Johnson SE, et al. Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther. 1989 ; 251: 150-155
13. Berman RM, Fava M, Thse ME, et al. Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009 ; 14: 197-206
14. Berridge KC, Kringelbach ML. Affective neuroscience of pleasure: Reward in humans and animals. Psychopharmacology (Berl). 2008 ; 199: 457-480
15. Bertschy G, Luxembourger I, Bizouard P, et al. Amineptin dependence. Detection of patients at risk. Report of 8 cases (in French). L'Encéphale. 1990 ; 16: 405-409
16. Bevins RA, Wilkinson JL, Palmatier MI, et al. Characterization of nicotine's ability to serve as a negative feature in Pavlovian appetitive conditioning task in rats. Psychopharmacol. 2006 ; 184: 470-481
17. Blier P, Briley M. The noradrenergic symptom cluster: Clinical expression and neuropharmacology. Neuropsychiatr Dis Treat. 2011 ; 7: 15-20
18. Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry. 2005 ; 66: 30-40
19. Bodkin JA, Lasser RA, Wines JD, et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry. 1997 ; 58: 137-145
20. Bonnet JJ, Chagraoui A, Protais P, et al. Interactions of amineptine with the neuronal dopamine uptake system: Neurochemical in vitro and in vivo studies. J Neural Transm. 1987 ; 69: 211-220
21. Borsook D, Becerra L, Fava M. Use of functional imaging across clinical phases in CNS drug development. Transl Psychiatry. 2013 ; 3: e282
22. Boyer P, Lecrubier Y, Stalla-Bourdillon A, et al. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology. 1999 ; 39: 25-32
23. Brady LS, Insel TR. Translating discoveries into medicine: Psychiatric drug development in 2011. Neuropsychopharmacology Rev. 2012 ; 37: 281-283
24. Bragulat V, Paillère-Martinot ML, Artiges E, et al. Dopaminergic function in depressed patients with affective flattening or with impulsivity: [18F]fluoro-L-dopa positron emission tomography study with voxel-based analysis. Psychiatry Res. 2007 ; 154: 115-124
25. Bramanti P, Bianchi L, Benedetto M, et al. Study of the hypnic effect of amineptine evaluation by means of polygraphy and tests. Prog Neuropsychopharmacol Biol Psychiatry. 1985 ; 9: 157-165
26. Bremner JD, Abrahams LM, Crupie JE, et al. Multicenter double-blind comparison of nomifensine and imipramine for efficacy and safety in depressed outpatients. J Clin Psychiatry. 1984 ; 45: 56-59
27. Candy M, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev. 2008 ; 2: CD006722
28. Cassano P, Lattanzi L, Fava M, et al. Ropinirole in treatment-resistant depression: A 16-week pilot study. Can J Psychiatry. 2005 ; 50: 357-360
29. Castot A, Benzaken C, Wagniart F, et al. Amineptin abuse. Analysis of 155 cases. An evaluation of the official cooperative survey of the Regional Centers of Pharmacovigilance (in French). Thérapie. 1990 ; 45: 399-405
30. Ceci A, Garattini S, Gobbi M, et al. Effect of long-term amineptine on pre- and post-synaptic mechanisms in rat brain. Br J Pharmacol. 1986 ; 88: 269-275
31. Channabasavanna SM, Khanna S. Therapy with amineptine, a dopamine reuptake inhibitor, in patients with major depression. Indian J Psychiatry. 1997 ; 39: 147-153
32. Chavez C, Hollaus M, Scarr E, et al. The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: An autoradiography study. Brain Res. 2010 ; 1321: 51-59
33. Chen PS, Yang YK, Yeh TL, et al. Correlation between body mass index and striatal dopamine transporter availability in healthy volunteers - a SPECT study. Neuroimage. 2008 ; 40: 275-279
34. Clerc GE, Ruimy P, Verdeau Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol. 1994 ; 9: 139-143
35. Cohn MA, Fredrickson BL, Brown SL, et al. Happiness unpacked: Positive emotions increase life satisfaction by building resilience. Emotion. 2009 ; 9: 361-368
36. Cooper JA, Tucker VL, Papakostas GI. Resolution of sleepiness and fatigue: A comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. J Psychopharmacol. 2014 ; 28: 118-124
37. Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety. 2000 ; 11: 58-65
38. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002 ; 63: 963-971
39. Dalery J, Rochat C, Peyron E, et al. Etude comparative de l'efficacité et de l'acceptabilité de l'amineptine et de la fluoxétine chez des patients dépressifs majeurs. L'Encéphale. 1992 ; 18: 257-262
40. Dalery J, Rochat C, Peyron E, et al. The efficacy and acceptability of amineptine versus fluoxetine in major depression. Int Clin Psychopharmacol. 1997 ; 12: S35 - S38
41. Darwish M, Bond M, Ezzet F. Armodafinil and modafinil in patients with excessive sleepiness associated with shift work disorder: a pharmacokinetic/pharmacodynamic model for predicting and comparing their concentration-effect relationships. J Clin Pharmacol. 2012 ; 52: 1328-1342
42. Davis C, Fattore L, Kaplan AS, et al. The suppression of appetite and food consumption by methylphenidate: The moderating effects of gender and weight status in healthy adults. Int J Neuropsychopharmacol. 2012 ; 15: 181-187
43. Delgado MR, Li J, Schiller D, et al. The role of the striatum in aversive learning and aversive prediction errors. Philos Trans R Soc Lond B Biol Sci. 2008 ; 363: 3787-3800
44. DeLorenzo C, Lichenstein S, Schaefer K, et al. SEP-225289 serotonin and dopamine transporter occupancy: A PET study. J Nucl Med. 2011 ; 52: 1150-1155
45. Deniker P, Besancon G, Colonna L, et al. Extensive multicentric study of 1354 cases of depressed subjects treated with amineptin (in French). L'Encéphale. 1982 ; 8: 355-370
46. Deniker P, Lôo H, Zarifian E, et al. Amineptine and amotival syndrome (author's transl.). L'Encéphale. 1981 ; 7: 59-64
47. Depue RA, Collins PF. Neurobiology of the structure of personality: Dopamine, facilitation of incentive motivation, and extraversion. Behav Brain Sci. 1999 ; 22: 491-569
48. Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci. 2012 ; 35: 68-77
49. Di Benedetto B, Rupprecht R. Targeting glia cells: Novel perspectives for the treatment of neuropsychiatric diseases. Curr Neuropharmacol. 2013 ; 11: 171-185
50. Dichter GS, Damiano CA, Allen JA. Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: Animal models and clinical findings. J Neurodev Disord. 2012a ; 4: 19
51. Dichter GS, Kozink RV, McClernon FJ, et al. Remitted major depression is characterized by reward network hyperactivation during reward anticipation and hypoactivation during reward outcomes. J Affect Disord. 2012b ; 136: 1126-1134
52. Dietz LJ, Birmaher B, Williamson DE, et al. Mother-child interactions in depressed children and children at high risk and low risk for future depression. J Am Acad Child Adolesc Psychiatry. 2008 ; 7: 574-582
53. Di Matteo V, De Blasi A, Di Giulio CD, et al. Role of 5-HT2C receptors in control of central dopamine function. Trends Pharmacol Sci. 2001 ; 22: 229-232
54. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007 ; 64: 327-337
55. Dwoskin LP, Rauhut AS, King-Pospisil KA, et al. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev. 2006 ; 12: 178-207
56. Dzirasa K, Fuentes R, Kumar S, et al. Chronic in vivo multi-circuit neurophysiological recordings in mice. J Neurosci Methods. 2011 ; 195: 36-46
57. Ebert D, Feistel H, Loew T, et al. Dopamine and depression-striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology (Berl). 1996 ; 126: 91-94
58. Elovainio M, Jokela M, Kivimaki M, et al. Genetic variants in the DRD2 gene moderate the relationship between stressful life events and depressive symptoms in adults: Cardiovascular risk in young Finns study. Psychosom Med. 2007 ; 69: 391-395
59. European Medicines Agency/Committee for Medicinal Products for Human Use (EMA/CHMP) (2013) Guideline on clinical investigation of medicinal products in the treatment of depression. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/05/WC500143770.pdf (accessed 20December2013).
60. Euthymics Bioscience, Inc (2013) Euthymics reports top-line results from TRIADE trial of amitifadine for major depressive disorder. Poster presentation at the NCDEU annual meeting exploring second indication in alcohol abuse disorder, Cambridge, MA, 29May2013. Available at: http://euthymics.com/wp-content/uploads/2013/05/FINAL-Euthymics-TRIADE-Results-052913.pdf.
61. Fava M, Thase ME, DeBattista C, et al. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry. 2007 ; 19: 153-159
62. Fekadu A, Wooderson SC, Markopoulo K, et al. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord. 2009 ; 116: 4-11
63. Folkman S, Moskowitz JT. Positive affect and the other side of coping. Am Psychol. 2000 ; 55: 647-654
64. Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims. Fed Reg. 2009 ; 74: 65132-65133
65. Forbes EE, Brown SM, Kimak M, et al. Genetic variation in components of dopamine neurotransmission impacts ventral striatal reactivity associated with impulsivity. Mol Psychiatry. 2009a ; 14: 60-70
66. Forbes EE, Hariri AR, Martin SL, et al. Altered striatal activation predicting real-world positive affect in adolescent major depressive disorder. Am J Psychiatr. 2009b ; 166: 64-73
67. Forbes EE, Shaw DS, Dahl RE. Alterations in reward-related decision making in boys with recent and future depression. Biol Psychiatry. 2007 ; 61: 633-639
68. Fostick L, Silberman A, Beckman M, et al. The economic impact of depression: Resistance or severity?. Eur Neuropsychopharmacol. 2010 ; 20: 671-675
69. Fowler JS, Volkow ND, Logan J, et al. Fast uptake and long-lasting binding of methamphetamine in the human brain: Comparison with cocaine. Neuroimage. 2008 ; 43: 756-763
70. Fredrickson BL. The broaden-and-build theory of positive emotions. Philos Trans R Soc Lond B Biol Sci. 2004 ; 359: 1367-1378
71. Freeman H. Early onset of action of amineptine. Int Clin Psychopharmacol. 1997 ; 12: S29 - S33
72. Garattini S. Pharmacology of amineptine, an antidepressant agent acting on the dopaminergic system: A review. Int Clin Psychopharmacol. 1997 ; 12: S15 - S19
73. Garattini S, Mennini T. Pharmacology of amineptine: Synthesis and updating. Clin Neuropharmacol. 1989 ; 12: S13 - S18
74. Garland EJ, Baerg EA. Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents. J Child Adolesc Psychopharmacol. 2001 ; 11: 181-186
75. Garrett BE, Rose CA, Henningfield JE. Tobacco addiction and pharmacological interventions. Expert Opin Pharmacother. 2001 ; 2: 1545-1555
76. Gaynes BN, Farley JF, Dusetzina SB, et al. Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?. Depress Anxiety. 2011 ; 28: 989-998
77. Georgiades K, Lewinsohn PM, Monroe SM, et al. Major depressive disorder in adolescence: The role of subthreshold symptoms. J Am Acad Child Adolesc Psychiatry. 2006 ; 45: 936-944
78. Gerson SC, Baldessarini R. Motor effects of serotonin in the central nervous system. Life Sci. 1980 ; 27: 1435-1451
79. Geschwind N, Nicolson NA, Peeters F, et al. Early improvement in positive rather than negative emotion predicts remission from depression after pharmacotherapy. Eur Neuropsychopharmacol. 2011a ; 21: 241-247
80. Geschwind N, Peeters F, Drukker M, et al. Mindfulness training increases momentary positive emotions and reward experience in adults vulnerable to depression: A randomized controlled trial. J Consult Clin Psychol. 2011b ; 79: 618-628
81. Geschwind N, Peeters F, Jacobs N, et al. Meeting risk with resilience: High daily life reward experience preserves mental health. Acta Psychiatr Scand. 2010 ; 122: 129-138
82. Gobert A, Rivet JM, Lejeune F, et al. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat. Synapse. 2000 ; 36: 205-221
83. Gobbi G, Slater S, Boucher N, et al. Neurochemical and psychotropic effects of buproprion in healthy male subjects. J Clin Psychopharmacol. 2003 ; 23: 233-239
84. Gold LH, Balster RL. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berl). 1996 ; 126: 286-292
85. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment resistant bipolar depression. Am J Psychiatry. 2004 ; 161: 564-566
86. Goldstein BJ, Goodnick PJ. SSRIs in the treatment of affective disorders - III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol. 1998 ; 12: S55 - S88
87. Golembiowska K, Kowalska M, Bymaster FP. Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity. Synapse. 2012 ; 66: 435-444
88. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders -II. Efficacy and quality of life. J Psychopharmacol. 1998 ; 12: S21 - S54
89. Goss AJ, Kaser M, Costafreda SG, et al. Modafinil augmentation therapy in unipolar and bipolar depression: A systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013 ; 74: 1101-1107
90. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry. 2001 ; 62: 26-31
91. Grimwood S, Hartig PR. Target site occupancy: Emerging generalizations from clinical and preclinical studies. Pharmacol Ther. 2009 ; 122: 281-301
92. Guelfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry. 1995 ; 56: 450-458
93. Guiard BP, El Mansari M, Merali Z, et al. Functional interactions between dopamine, serotonin and norepinephrine neurons: An in-vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol. 2008 ; 11: 625-639
94. Habibi B, Cartron JP, Bretagne M, et al. Anti-nomifensine antibody causing immune hemolytic anemia and renal failure. Vox Sang. 1981 ; 40: 79-84
95. Haddad P. Do antidepressants have any potential to cause addiction?. J Psychopharmacol. 1999 ; 13: 300-307
96. Haddjeri N, de Montigny C, Blier P. Modulation of the firing activity of noradrenergic neurones in the rat locus coeruleus by the 5-hydroxtryptamine system. Br J Pharmacol. 1997 ; 120: 865-875
97. Haeffel GJ, Getchell M, Koposov RA, et al. Association between polymorphisms in the dopamine transporter gene and depression: Evidence for a gene-environment interaction in a sample of juvenile detainees. Psychol Sci. 2008 ; 19: 62-69
98. Hannestad J, Gallezot JD, Planeta-Wilson B, et al. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry. 2010 ; 68: 854-860
99. Hardy SE. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. Am J Geriatr Pharmacother. 2009 ; 7: 34-59
100. Hasler G, Northoff G. Discovering imaging endophenotypes for major depression. Mol Psychiatry. 2011 ; 16: 604-619
101. Hasler G, Drevets WC, Manji HK, et al. Discovering endophenotypes for major depression. Neuropsychopharmacology. 2004 ; 29: 1765-1781
102. Hasler G, Fromm S, Carlson PJ, et al. Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry. 2008 ; 65: 521-531
103. Hayes PE, Kristoff CA. Adverse reactions to five new antidepressants. Clin Pharm. 1986 ; 5: 471-480
104. Heller AS, Johnstone T, Light SN, et al. Relationships between changes in sustained fronto-striatal connectivity and positive affect in major depression resulting from antidepressant treatment. Am J Psychiatry. 2013 ; 170: 197-206
105. Hoehn-Saric R, Harris GJ, Pearlson GD, et al. A fluoxetine-induced frontal lobe syndrome in an obsessive compulsive patient. J Clin Psychiatry. 1991 ; 52: 131-133
106. Hoehn-Saric R, Lipsey JR, McLeod DR. Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol. 1990 ; 10: 343-345
107. Hsiao M-C, Lin K-J, Liu C-Y, et al. The interaction between dopamine transporter function, gender differences, and possibility laterality in depression. Psychiatry Res. 2013 ; 211: 72-77
108. Ichikawa J, Meltzer HY. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci. 1999 ; 249: 90-98
109. Jafarinia M, Mohammadi MR, Modabbernia A, et al. Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: Randomized double-blind study. Hum Psychopharmacol. 2012 ; 27: 411-418
110. Jamerson BD, Krishnan KR, Roberts J, et al. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression. Psychopharmacol Bull. 2003 ; 37: 67-78
111. Jansen W, Siegfried K. Nomifensine in geriatric inpatients: A placebo-controlled study. J Clin Psychiatry. 1984 ; 45: 63-67
112. Jasinski DR, KovaceviÄ-RistanoviÄ R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol. 2000 ; 23: 149-156
113. Jimerson DC. Neurotransmitter hypotheses of depression. Research update. Psychiatr Clin North Am. 1984 ; 7: 563-573
114. Kaffman A, Krystal JH. New frontiers in animal research of psychiatric illness. Methods Mol Biol. 2012 ; 829: 3-30
115. Kasch KL, Rottenberg J, Arnow BA, et al. Behavioral activation and inhibition systems and the severity and course of depression. J Abnorm Psychol. 2002 ; 111: 589-597
116. Knutson B, Cooper JC. Functional magnetic resonance imaging of reward prediction. Curr Opin Neurol. 2005 ; 18: 411-417
117. Koob GF. Neurobiology of addiction: Toward the development of new therapies. Ann N Y Acad Sci. 2000 ; 909: 170-185
118. Kozel FA, Trivedi MH. Developing a neuropsychiatric functional brain imaging test. Neurocase. 2007 ; 14: 54-58
119. Kozel FA, Rao U, Lu H, et al. Functional connectivity of brain structures correlates with treatment outcome in major depressive disorder. Front Psychiatry. 2011 ; 2: 1-7
120. Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology. 2003 ; 28: 413-420
121. Lambert G, Johansson M, Agren H, et al. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: Evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry. 2000 ; 57: 7877-7893
122. Lane RM. A critical review of SSRI-related sexual dysfunction, incidence, possible aetiology and implications for management. J Psychopharmacol. 1997 ; 11: 72-82
123. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: Implications for treatment. J Psychopharmacol. 1998 ; 12: 208-230
124. Lane RM. Restoration of positive mood states in major depression as a potential drug development target. J Psychopharmacol. 2014 ; 28: 527-535
125. Lapidus KAB, Soleimani L, Murrough JW. Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat. 2013 ; 9: 1101-1112
126. Lazaros GA, Stavrinos C, Papatheodoridis GV, et al. Amineptine induced liver injury. Report of two cases and brief review of the literature. Hepatogastroenterology. 1996 ; 43: 1015-1019
127. Learned S, Graff O, Roychowdhury S, et al. Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: Two randomized, placebo- and active-controlled clinical trials. J Psychopharmacol. 2012 ; 26: 653-662
128. Learned-Coughlin SM, Bergstrom M, Savitcheva I, et al. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry. 2003 ; 54: 800-805
129. Lengyel K, Pieschl R, Stong T, et al. Ex vivo assessment of binding site occupancy of monoamine reuptake inhibitors: Methodology and biological significance. Neuropharmacology. 2008 ; 55: 63-70
130. Lenox-Smith AJ, Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol. 2008 ; 23: 113-119
131. Li X, Frye MA, Shelton RC. Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology. 2012 ; 37: 77-101
132. Lobo MK, Nestler EJ, Covington HE. Potential utility of optogenetics in the study of depression. Biol Psychiatry. 2012 ; 71: 1068-1074
133. Lundberg J, Tiger M, Landén M, et al. Serotonin transporter occupancy with TCAs and SSRIs: A PET study in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012 ; 15: 1167-1172
134. Malhi GS, Berk M. Does dopamine dysfunction drive depression?. Acta Psychiatr Scand Suppl. 2007 ; 433: 116-124
135. Malhi GS, Parker GB, Crawford J, et al. Treatment-resistant depression: Resistant to definition?. Acta Psychiatr Scand. 2005 ; 112: 302-309
136. Martinez JM, Katon W, Greist JH, et al. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode. Int Clin Psychopharmacol. 2012 ; 27: 17-26
137. Martinot M, Bragulat V, Artiges E, et al. Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am J Psychiatry. 2001 ; 158: 314-316
138. McCabe C, Cowen PJ, Harmer CJ. Neural representation of reward in recovered depressed patients. Psychopharmacology (Berl). 2009 ; 205: 667-677
139. McCabe C, Mishor Z, Cowen PJ, et al. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry. 2010 ; 67: 439-445
140. McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011 ; 31: 180-186
141. McElroy S, Mitchell J, Wilfley D, et al. Lisdexamfetamine dimesylate safety and efficacy on binge eating days/episodes and behavior in adults with moderate to severe binge eating disorder. Poster #NR4-25 at the 166th annual meeting of the American Psychiatric Association ; 2013 San Francisco, CA, USA ; 2013..
142. McGrath PJ, Quitkin FM, Klein DF. Bromocriptine treatment of relapses seen during selective serotonin re-uptake inhibitor treatment of depression. J Clin Psychopharmacol. 1995 ; 15: 289-291
143. McMakin DL, Olino TM, Porta G, et al. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J Am Acad Child Adolesc Psychiatry. 2012 ; 51: 404-411
144. Meyer JH, Goulding VS, Wilson AA, et al. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl). 2002 ; 163: 102-105
145. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [11C]DASB positron emission tomography study. Am J Psychiatry. 2004 ; 161: 826-835
146. Millan MJ. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: Novel concepts, new drugs. Neurother. 2009 ; 6: 53-77
147. Montejo AL, Llorca G, Izquierdo JA, et al. Sexual dysfunction with antidepressive agents. Effect of the change to amineptine in patients with sexual dysfunction secondary to SSRI (in Spanish). Actas Esp Psiquiatr. 1999 ; 27: 23-34
148. Montgomery SA. Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders. Int Clin Psychopharmacol. 2002 ; 17: S16 - S17
149. Moos RH, Cronkite RC. Symptom-based predictors of a 10-year chronic course of treated depression. J Nerv Ment Dis. 1999 ; 187: 360-368
150. Moroz G, Magni G, Fava M. Update on "open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder.". J Clin Psychopharmacol. 2000 ; 20: 285
151. Nelson JC. Synergistic benefits of serotonin and noradrenaline reuptake inhibition. Depress Anxiety. 1998 ; 7: 5-6
152. Nemeroff CB. The burden of severe depression: A review of diagnostic challenges and treatment alternatives. J Psychiat Res. 2006 ; 41: 189-206
153. Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nat Neurosci. 2010 ; 13: 1161-1169
154. Ng B. Is there a role for psychostimulants in old age depression and apathy?. Int Psychogeriatr. 2009 ; 21: 417-418
155. Nierenberg AA, Bently KH, Farabaugh AH, et al. The absence of depressive symptoms is not the presence of wellness: Validation of the clinical positive affect scale. Aust NZ J Psychiatry. 2012 ; 46: 1165-1172
156. Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: A STAR∗D report. Psychol Med. 2010 ; 40: 41-50
157. Nikolova YS, Bogdan R, Brigidi BD, et al. Ventral striatum reactivity to reward and recent life stress interact to predict positive affect. Biol Psychiatry. 2012 ; 72: 157-163
158. Nikolova YS, Ferrell RE, Manuck SB, et al. Multilocus genetic profile for dopamine signaling predicts ventral striatum reactivity. Neuropsychopharmacology. 2011 ; 36: 1940-1947
159. Nutt D, Goodwin G. ECNP summit on the future of CNS drug research in Europe 2011: Report prepared for ECNP by David Nutt and Guy Goodwin. Eur Neuropsychopharmacol. 2011 ; 21: 495-499
160. Nutt D, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: The role of catecholamines in causation and cure. J Psychopharmacol. 2007 ; 21: 461-471
161. Opbroek A, Delgado PL, Laukes C, et al. Emotional blunting associated with SSRI-induced sexual dysfunction: Do SSRIs inhibit emotional responses?. Int J Neuropsychopharmacol. 2002 ; 5: 147-151
162. Ostow M. Pramipexole for depression. Am J Psychiatry. 2002 ; 159: 320-321
163. Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol. 2006 ; 16: 391-402
164. Papakostas GI, Trivedi MH, Alpert JE, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: A meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res. 2008 ; 42: 134-140
165. Parker G. Is the diagnosis of melancholia important in shaping clinical management?. Curr Opin Psychiatry. 2007 ; 20: 197-201
166. Parker G. Classifying clinical depression: An operational proposal. Acta Psychiatr Scand. 2011 ; 123: 314-316
167. Parker G, Brotchie H. Do the old psychostimulant drugs have a role in managing treatment-resistant depression?. Acta Psychiatr Scand. 2010 ; 121: 308-314
168. Paterson NE, Balfour DJ, Markou A. Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur J Neurosci. 2007 ; 25: 3099-3108
169. Paul IA, Nowak G, Layer RT, et al. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther. 1994 ; 269: 95-102
170. Pine DS, Cohen E, Cohen P, et al. Adolescent depressive symptoms as predictors of adult depression: Moodiness or mood disorder?. Am J Psychiatry. 1999 ; 156: 133-135
171. Pizzagalli DA, Holmes AJ, Dillon DG, et al. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry. 2009 ; 166: 702-710
172. Platt ML, Huettel SA. Risky business: The neuroeconomics of decision making under uncertainty. Nat Neurosci. 2008 ; 11: 398-403
173. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry. 1999 1999 ; 175: 12-16
174. Post RM, Gerner RH, Carman JS, et al. Effects of a dopamine agonist piribedil in depressed patients: Relationship of pretreatment homovanillic acid to antidepressant response. Arch Gen Psychiatr. 1978 ; 35: 609-615
175. Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: Qualitative study. Br J Psychiatry. 2009 ; 195: 211-217
176. Prins J, Olivier B, Korte SM. Triple reuptake inhibitors for treating subtypes of major depressive disorder: The monoamine hypothesis revisited. Expert Opin Investig Drugs. 2011 ; 20: 1107-1130
177. Prisco S, Esposito E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br J Pharmacol. 1995 ; 116: 1923-1931
178. Prisco S, Pagannone S, Esposito E. Serotonin-dopamine interaction in the rate ventral tegmental area: An electrophysiological study in vivo. J Pharmacol Exp Ther. 1994 ; 271: 83-90
179. Rampello L, Nicoletti G, Raffaele R. Dopaminergic hypothesis for retarded depression: A symptom profile for predicting therapeutical responses. Acta Psychiatr Scand. 1991 ; 84: 552-554
180. Rampello L, Nicoletti G, Raffaele R, et al. Comparative effects of amitriptyline and amineptine in patients affected by anxious depression. Neuropsychobiology. 1995 ; 31: 130-134
181. Rau KS, Birdsall E, Hanson JE, et al. Bupropion increases striatal vesicular monoamine transport. Neuropharmacology. 2005 ; 49: 820-830
182. Ravindran AV, Kennedy SH, O'Donovan MC, et al. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: Results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2008 ; 69: 87-94
183. Ressler KJ, Mayberg HS. Targeting abnormal neural circuits in mood and anxiety disorders: From the laboratory to the clinic. Nat Neurosci. 2007 ; 10: 1116-1124
184. Riddle EL, Fleckenstein AE, Hanson GR. Role of monoamine transporters in mediating psychostimulant effects. AAPS J. 2005 ; 7: E847-851
185. Rief W, Nestoriuc Y, Weiss S, et al. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord. 2009 ; 118: 1-8
186. Robinson OJ, Cools R, Carlisi CO, et al. Ventral striatum response during reward and punishment reversal learning in unmedicated major depressive disorder. Am J Psychiatry. 2012 ; 169: 152-159
187. Rosen R, Menza M, Lane R. Effects of SSRIs on sexual dysfunction: Critical review. J Clin Psychopharmacol. 1999 ; 19: 67-85
188. Rottenberg J, Kasch KL, Gross JJ, et al. Sadness and amusement reactivity differentially predict concurrent and prospective functioning in major depressive disorder. Emotion. 2002 ; 2: 135-146
189. Rush AJ, Trivedi MH, Stewart AA, et al. Combining medications to enhance depression outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011 ; 168: 689-701
190. Rush AJ, Warden D, Wisniewski SR, et al. STAR∗D: Revising conventional wisdom. CNS Drugs. 2009 ; 23: 627-647
191. Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. Nat Rev. 2013 ; 14: 609-625
192. Scarzella L, Scarzella R, Mailland F, et al. Amineptine in the management of the depressive syndromes. Prog Neuropsychopharmacol Biol Psychiatry. 1985 ; 9: 429-439
193. Schacht U, Leven M, Gerhards HJ, et al. Recent investigations on the mechanism of action of nomifensine. Int Pharmacopsychiatry. 1982 ; 17: 21-34
194. Schreiber R, Lew R, Hardy L, et al. Pharmacological characterization of the triple monoamine transporter inhibitor SEP-225289. Paper presented at the Meeting of the Society for Neuroscience ; 2009 Chicago, IL, USA ; 2009..
195. Schroeder M, Krebs MO, Bleich S, et al. Epigenetics and depression: Current challenges and new therapeutic options. Curr Opin Psychiatry. 2010 ; 23: 588-592
196. Seibyl JP, Tabamo R, Jennings D, et al. NS2359 demonstrates dose-related dopamine and serotonin transporter occupancy in healthy male subjects with 123-l a-CIT SPECT imaging. Neurology. 2004 ; 62: A305
197. Seth R, Jennings AL, Bindman J, et al. Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry. 1992 ; 161: 562-565
198. Sheeber LB, Allen NB, Leve C, et al. Dynamics of affective experience and behavior in depressed adolescents. J Child Psychol Psychiatry. 2009 ; 50: 1419-1427
199. Shekim WO, Masterson A, Cantwell DP, et al. Nomifensine maleate in adult attention deficit disorder. J Nerv Ment Dis. 1989 ; 177: 296-299
200. Shelton RC, Tomarken AJ. Review: Can recovery from depression be achieved?. Psychiatr Serv. 2001 ; 52: 1469-1478
201. ShirePLC (2014) Shire reports top-line results from two Phase 3 studies for Vyvanse® (lisdexamfetamine dimesylate) capsules (CII) as an adjunctive treatment for adults with major depressive disorder. Available at: http://www.shire.com/shireplc/en/investors/investorsnews/irshirenews?id=921 (accessed 20 May 2014).
202. Shoedel KA, Meier D, Chakraborty B, et al. Subjective and objective effects of the novel triple reuptake inhibitor tesofenosine in recreational stimulant users. Clin Pharmacol Ther. 2010 ; 88: 69-78
203. Sitland-Marken PA, Wells BG, Froemming JH, et al. Psychiatric applications of bromocriptine therapy. J Clin Psychiatry. 1990 ; 51: 68-82
204. Skolnick P, Krieter P, Tizzano J, et al. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Rev. 2006 ; 12: 123-124
205. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry. 2006 ; 67: 16-22
206. Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry. 2006 ; 163: 387-395
207. Spencer TJ, Madras BK, Bonab AA, et al. A positron emission tomography study examining the dopaminergic activity of armodafinil in adults using [11C]altropane and [11C]raclopride. Biol Psychiatry. 2010 ; 68: 964-970
208. Spijker J, Bijl RV, de Graaf R, et al. Determinants of poor 1-year outcome of DSM-III-R major depression in the general population: Results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr Scand. 2001 ; 103: 122-130
209. Stahl SM Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge: Cambridge University Press ; 2008 :
210. Stahl SM. Mechanism of action of detromethorphan/quinidine: Comparison with ketamine. CNS Spectrums. 2013 ; 18: 225-227
211. Steinbusch HWM Handbook of Chemical Neuroanatomy. Bjorklun A Hokfelt T Kuhar MJ, ed. Amsterdam: Elsevier ; 1984: 68-125.
212. Stewart JW, McGrath PJ, Blondeau C, et al. Combination antidepressant therapy for major depressive disorder: Speed and probability of remission. J Psychiatr Res. 2014 ; 52: 7-14
213. Stoll AL, Pillay SS, Diamond L, et al. Mehyphenidate augmentation of selective serotonin reuptake inhibitors: A case series. J Clin Psychiatry. 1996 ; 57: 72-76
214. Stoops WW, Lile JA, Fillmore MT, et al. Reinforcing effects of modafinil: Influence of dose and behavioral demands following drug administration. Psychopharmacology (Berl). 2005 ; 182: 186-193
215. Sussman M, Stahl S. Update in the pharmacotherapy of depression. Am J Med. 1996 ; 101: 26S - 36S
216. Takano A, Suzuki K, Kosaka J, et al. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl). 2006 ; 185: 395-399
217. Tatsumi M, Groshan K, Blakely RD, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 ; 340: 249-258
218. Thase ME. Are SNRIs more effective than SSRIs? A review of the current state of the controversy. Psychopharmacol Bull. 2008 ; 41: 58-85
219. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001 ; 178: 234-241
220. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: A meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 2005 ; 66: 974-981
221. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 ; 12: 185-219
222. Tomarken AJ, Dichter GS, Freid C, et al. Assessing the effects of Bupropion SR on mood dimensions of depression. J Affect Disord. 2004 ; 78: 235-241
223. Tran P, Skolnick P, Czobor P, et al. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. J Psych Res. 2012 ; 46: 64-71
224. Treadway MT, Zald DH. Reconsidering anhedonia in depression: Lessons from translational neuroscience. Neurosci Biobehav Rev. 2011 ; 35: 537-555
225. Treadway MT, Bossaller NA, Shelton RC, et al. Effort-based decision-making in major depressive disorder: A translational model of motivational anhedonia. J Abnorm Psychol. 2012 ; 121: 553-558
226. Treadway MT, Buckholtz JW, Schwartzman AN, et al. Worth the "EEfRT"? The effort expenditure for rewards task as an objective measure of motivation and anhedonia. PLoS One. 2009 ; 4: e6598
227. Tremblay P, Blier P. Catcholaminergic strategies for the treatment of major depression. Curr Durg Targets. 2006 ; 7: 149-158
228. Tremblay LK, Naranjo CA, Cardenas L, et al. Probing brain reward system function in major depressive disorder: Altered response to dextroamphetamine. Arch Gen Psychiatr. 2002 ; 59: 409-416
229. Tremblay LK, Naranjo CA, Graham SJ, et al. Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatr. 2005 ; 62: 1228-1236
230. Trivedi MH, Cutler AJ, Richards C, et al. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. J Clin Psychiatry. 2013 ; 74: 802-809
231. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006 ; 354: 1243-1252
232. Trivedi MH, Rush AJ, Carmody TJ, et al. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?. J Clin Psychiatry. 2001 ; 62: 776-781
233. MA, USA: Impact report, Tufts Center for the Study of Drug Development ; 2013 :
234. Tugade MM, Fredrickson BL. Resilient individuals use positive emotions to bounce back from negative emotional experiences. J Pers Soc Psychol. 2004 ; 86: 320-333
235. Uher R, Perlis RH, Henigsberg N, et al. Depression symptom dimensions as predictors of antidepressant treatment outcome: Replicable evidence for interest-activity symptoms. Psychol Med. 2012a ; 42: 967-980
236. Uher R, Perlis RH, Placentino A, et al. Self-report and clinician-rated measures of depression severity: Can one replace the other?. Depress Anxiety. 2012b ; 29: 1043-1049
237. Ustun TB, Aryuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004 ; 184: 386-392
238. van Amerongen P. Objective evaluation of the effectiveness of amineptine in the treatment of severe depressive states using the Hamilton depression scale (in French). L'Encéphale. 1978 ; 4: 131-143
239. van Amerongen P. Double-blind clinical trial of the antidepressant action of amineptine. Curr Med Res Opin. 1979 ; 6: 93-100
240. van der Schaaf ME, Warmerdamc E, Crone EA, et al. Distinct linear and non-linear trajectories of reward and punishment reversal learning during development: Relevance for dopamine's role in adolescent decision making. Dev Cognit Neurosci. 2011 ; 1: 578-590
241. Vaugeois JM, Corera AT, Deslandes A, et al. Although chemically related to amineptine, the antidepressant tianeptine is not a dopamine uptake inhibitor. Pharmacol Biochem Behav. 1999 ; 63: 285-290
242. Vauterin C, Bazot M. A double-blind controlled trial of amineptine versus trimipramine in depression. Curr Med Res Opin. 1979 ; 6: 101-106
243. Videbech P. Modafinil in the treatment of depression. Ugeskr Laeger. 2012 ; 174: 348-351
244. Volkow ND, Li TK. Drug addiction: The neurobiology of behaviour gone awry. Nat Rev Neurosci. 2004 ; 5: 963-970
245. Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: Clinical implications. JAMA. 2009 ; 301: 1148-1154
246. Volkow ND, Fowler JS, Wang G, et al. Mechanism of action of methylphenidate: Insights from PET imaging studies. J Atten Disord. 2002a ; 6: S31 - S43
247. Volkow ND, Wang GJ, Fischman MW, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature. 1997 ; 386: 827-830
248. Volkow ND, Wang GJ, Fowler JS, et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: Therapeutic implications. Synapse. 2002b ; 43: 181-187
249. Wardenaar KJ, Giltay EJ, van Veen T, et al. Symptom dimensions as predictors of the two-year course of depressive and anxiety disorders. J Affect Disord. 2012 ; 136: 1198e
250. Watson D. Rethinking the mood and anxiety disorders: A quantitative hierarchical model for DSM-V. J Abnorm Psychol. 2005 ; 114: 522-536
251. Watson D, Clark LA, Carey G. Positive and negative affectivity and their relation to anxiety and depressive disorders. J Abnorm Psychol. 1988 ; 97: 346-353
252. Weihs KL, Settle EC, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry. 2000 ; 61: 196-202
253. Wichers M, Aguilera M, Kenis G, et al. The catechol-O-methyl transferase Val158Met polymorphism and experience of reward in the flow of daily life. Neuropsychopharmacology. 2008a ; 33: 3030-3036
254. Wichers M, Geschwind N, Jacobs N, et al. Transition from stress sensitivity to a depressive state: Longitudinal twin study. Br J Psychiatry. 2009 ; 195: 498-503
255. Wichers M, Kenis G, Jacobs N, et al. The psychology of psychiatric genetics: Evidence that positive emotions in females moderate genetic sensitivity to social stress associated with the BDNF Val(66)Met polymorphism. J Abnorm Psychol. 2008b ; 117: 699-706
256. Wichers M, Menne-Lothmann C, Vercauteren P, et al. Positive affect and recovery from depression. Eur Neuropsychopharmacol. 2012 ; 22: S140
257. Wichers M, Peeters F, Geschwind N, et al. Unveiling patterns of affective responses in daily life improve outcome prediction in depression: A momentary assessment study. J Affect Disord. 2010 ; 124: 191-195
258. Wichers MC, Myin-Germeys I, Jacobs N, et al. Evidence that moment-to-moment variation in positive emotions buffers genetic risk for depression: A momentary assessment twin study. Acta Psychiatr Scand. 2007 ; 115: 451-457
259. Wilkinson MB, Xiao G, Kumar A, et al. Imipramine treatment and resiliency exhibit similar chromatin regulation in the mouse nucleus accumbens in depression models. J Neurosci. 2009 ; 29: 7820-7832
260. Willner P. Dopamine and depression: A review of recent evidence. I. Empirical studies. Brain Res. 1983 ; 287: 211-224
261. Willner P. Chronic mild stress (CMS) revisited: Consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology. 2005 ; 52: 90-110
262. Woodcock J, Griffin JP, Behrman RE. Development of novel combination therapies. N Engl J Med. 2011 ; 364: 985-987
263. Yakabow AL, Hardiman S, Nash RJ. An overview of side effects and long-term experience with nomifensine from United States clinical trials. J Clin Psychiatry. 1984 ; 45: 96-101
264. Yang YK, Yeh TL, Yao WJ, et al. Greater availability of dopamine transporters in patients with major depression - a dual-isotope SPECT study. Psychiatry Res. 2008 ; 162: 230-235
265. Zarate CA, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: A placebo-controlled proof of concept study. Biol Psychiatry. 2004 ; 56: 54-60
266. Zheng M, Appel L, Lane R, et al. Safety, pharmacokinetic and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-82083. 51st annual meeting of the American College of Neuropsychopharmacology ; 2012 Hollywood, FL ; 2012..
267. Zhou W, Cunningham KA, Thomas ML. Estrogen regulation of gene expression in the brain: A possible mechanism altering the response to psychostimulants in female rats. Brain Res Mol Brain Res. 2002 ; 100: 75-83